GPI-1485 | CAS#186268-78-0 | Neuroimmunophilin ligand

MedKoo Cat#: 565480 | Name: GPI-1485

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

GPI-1485 is a neuroimmunophilin ligand, binding to fk-506-binding proteins

Chemical Structure

GPI-1485

CAS#186268-78-0

Theoretical Analysis

MedKoo Cat#: 565480

Name: GPI-1485

CAS#: 186268-78-0

Chemical Formula: C12H19NO4

Exact Mass: 241.1314

Molecular Weight: 241.29

Elemental Analysis: C, 59.73; H, 7.94; N, 5.81; O, 26.52

Price and Availability

Size	Price	Availability
10mg	USD 350.00	2 Weeks
25mg	USD 650.00	2 Weeks
50mg	USD 950.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

GPI-1485; GPI 1485; GPI1485

IUPAC/Chemical Name

(2S)-1-(3,3-Dimethyl-2-oxopentanoyl)pyrrolidine-2-carboxylic acid

InChi Key

FOPALECPEUVCTL-QMMMGPOBSA-N

InChi Code

InChI=1S/C12H19NO4/c1-4-12(2,3)9(14)10(15)13-7-5-6-8(13)11(16)17/h8H,4-7H2,1-3H3,(H,16,17)/t8-/m0/s1

SMILES Code

O=C([C@H]1N(C(C(C(C)(C)CC)=O)=O)CCC1)O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

GPI-1485 (GM1485), a nonimmunosuppressive immunophilin ligand, promotes neurofunctional improvement and neural regeneration following stroke.

In vitro activity:

Additionally, GM1485-treated fibroblasts subjected to oxidative stress were reprogrammed to a stem-cell-like phenotype and were able to differentiate down a neuronal lineage. Reference: J Neurosci Res. 2012 Jul;90(7):1413-23. https://pubmed.ncbi.nlm.nih.gov/22431363/

In vivo activity:

GM1485-treated rats demonstrated improved neurological function as well as increased Sox2(+) cells in the ipsilateral SVZ and striatum relative to vehicle-treated rats. Reference: J Neurosci Res. 2012 Jul;90(7):1413-23. https://pubmed.ncbi.nlm.nih.gov/22431363/

	Solvent	mg/mL	mM
Solubility
	DMSO	100.0	414.44

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 241.29 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Ducruet AF, DeRosa PA, Zacharia BE, Sosunov SA, Connolly ES Jr, Weinstein DE. GM1485, a nonimmunosuppressive immunophilin ligand, promotes neurofunctional improvement and neural regeneration following stroke. J Neurosci Res. 2012 Jul;90(7):1413-23. doi: 10.1002/jnr.23033. Epub 2012 Mar 20. PMID: 22431363.

In vitro protocol:

In vivo protocol:

1: Parashos SA, Luo S, Biglan KM, Bodis-Wollner I, He B, Liang GS, Ross GW, Tilley BC, Shulman LM; NET-PD Investigators. Measuring disease progression in early Parkinson disease: the National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience. JAMA Neurol. 2014 Jun;71(6):710-6. doi: 10.1001/jamaneurol.2014.391. PubMed PMID: 24711047; PubMed Central PMCID: PMC4188544. 2: Ducruet AF, DeRosa PA, Zacharia BE, Sosunov SA, Connolly ES Jr, Weinstein DE. GM1485, a nonimmunosuppressive immunophilin ligand, promotes neurofunctional improvement and neural regeneration following stroke. J Neurosci Res. 2012 Jul;90(7):1413-23. doi: 10.1002/jnr.23033. Epub 2012 Mar 20. PubMed PMID: 22431363. 3: Elble RJ, Suchowersky O, Shaftman S, Weiner WJ, Huang P, Tilley B; NINDS NET-PD Investigators. Impact of belief in neuroprotection on therapeutic intervention in Parkinson's disease. Mov Disord. 2010 Jun 15;25(8):1082-6. doi: 10.1002/mds.22997. PubMed PMID: 20131372; PubMed Central PMCID: PMC2891220. 4: Parashos SA, Swearingen CJ, Biglan KM, Bodis-Wollner I, Liang GS, Ross GW, Tilley BC, Shulman LM; NET-PD Investigators. Determinants of the timing of symptomatic treatment in early Parkinson disease: The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) Experience. Arch Neurol. 2009 Sep;66(9):1099-104. doi: 10.1001/archneurol.2009.159. Epub 2009 Jul 13. PubMed PMID: 19597081; PubMed Central PMCID: PMC2839890. 5: NINDS NET-PD Investigators. A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology. 2007 Jan 2;68(1):20-8. PubMed PMID: 17200487. 6: Poulter MO, Payne KB, Steiner JP. Neuroimmunophilins: a novel drug therapy for the reversal of neurodegenerative disease? Neuroscience. 2004;128(1):1-6. Review. PubMed PMID: 15450348. 7: Marshall VL, Grosset DG. GPI-1485 (Guilford). Curr Opin Investig Drugs. 2004 Jan;5(1):107-12. Review. PubMed PMID: 14983983. 8: Iometopane: (123)I beta-CIT, dopascan injection, GPI 200, RTI 55. Drugs R D. 2003;4(5):320-2. Review. PubMed PMID: 12952503.